Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apalutamide + goserelin
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules, Peptides
- Administration
- Oral, Subcutaneous
01
Overview
A combination therapy consisting of the androgen receptor antagonist apalutamide and the gonadotropin-releasing hormone (GnRH) agonist goserelin. This regimen is being investigated for the treatment of androgen receptor (AR)-expressing locally advanced or recurrent/metastatic salivary gland carcinoma (SGC). Apalutamide is a nonsteroidal antiandrogen that acts as a selective competitive antagonist of the androgen receptor, blocking androgen-mediated gene transcription and nuclear translocation. Goserelin is a synthetic decapeptide analogue of GnRH that, upon chronic administration, leads to down-regulation of the pituitary GnRH receptors, resulting in a decrease in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, and a subsequent fall in serum testosterone levels to castrate levels. The combination aims to achieve maximal androgen blockade in AR-positive SGC, a rare malignancy that shares biological similarities with prostate cancer.
- Other names
- Apalutamide plus GnRH AgonistYATAGARASU regimen
02
Targets
AR (Adrenergic receptors)GABRR (GABA-A receptor subunit rho)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on apalutamide + goserelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apalutamide + goserelin.